We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+31.61%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.19B
AUM Growth
+$204M
Cap. Flow
+$48.2M
Cap. Flow %
4.04%
Top 10 Hldgs %
41.65%
Holding
184
New
58
Increased
50
Reduced
24
Closed
34

Top Buys

Rank Stock Value
1
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$22.4M
2
FOLD
Amicus Therapeutics
FOLD
+$14.4M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$13.8M
4
BLUE
bluebird bio
BLUE
+$11.6M
5
RLYP
RELYPSA INC COM
RLYP
+$11.3M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$24.3M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$18.9M
3
ARWR icon
Arrowhead Research
ARWR
+$18.4M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14.7M
5
HCA icon
HCA Healthcare
HCA
+$12.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.07%
2 Financials 0.1%
3 Energy 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THOR
26
DELISTED
THORATEC CORPORATION
THOR
$12.7M 1.07%
392,465
+244,964
+166% +$7.13M
XLRN
27
DELISTED
Acceleron Pharma
XLRN
$12.4M 1.04%
317,636
-127,364
-29% -$4.44M
ESPR
28
DELISTED
Esperion Therapeutics
ESPR
$12.2M 1.03%
+302,500
New +$9.26M
SGMO
29
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$12.2M 1.02%
800,000
– –
VRTX icon
30
PUT
Vertex Pharmaceuticals
VRTX
$122B
$11.9M 1%
+100,000
New +$11.3M
BDX icon
31
Becton Dickinson
BDX
$46.3B
$11.1M 0.93%
+82,000
New +$10.5M
INSM icon
32
Insmed
INSM
$22.4B
$10.6M 0.89%
685,812
+85,812
+14% +$1.22M
VNDA icon
33
CALL
Vanda Pharmaceuticals
VNDA
$304M
$8.59M 0.72%
+600,000
New +$7.1M
LRMR icon
34
Larimar Therapeutics
LRMR
$377M
$8.58M 0.72%
23,193
+276
+1% +$71.1K
QTNT
35
DELISTED
Quotient Limited Ordinary Shares
QTNT
$8.17M 0.69%
11,347
+4,751
+72% +$2.26M
EPZM
36
DELISTED
Epizyme, Inc
EPZM
$8.16M 0.68%
432,619
+148,729
+52% +$3.47M
MGNX icon
37
MacroGenics
MGNX
$235M
$7.57M 0.63%
215,815
+2,112
+1% +$52.6K
BDSI
38
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$7.28M 0.61%
605,407
+299,407
+98% +$4.55M
ELDN icon
39
Eledon Pharmaceuticals
ELDN
$258M
$7.15M 0.6%
2,996
+1,885
+170% +$4.48M
CHRS icon
40
Coherus Oncology
CHRS
$217M
$7.15M 0.6%
+438,000
New +$6.18M
NVRO
41
DELISTED
NEVRO CORP.
NVRO
$6.83M 0.57%
+176,563
New +$5.56M
HRTX icon
42
Heron Therapeutics
HRTX
$93.6M
$6.7M 0.56%
666,042
-219,310
-25% -$1.79M
SRPT icon
43
CALL
Sarepta Therapeutics
SRPT
$1.65B
$6.51M 0.55%
450,000
-800,000
-64% -$13.5M
AGTC
44
DELISTED
Applied Genetic Technologies Corporation
AGTC
$6.33M 0.53%
301,222
+4,244
+1% +$86.4K
AFMD
45
DELISTED
Affimed
AFMD
$6.24M 0.52%
100,582
+583
+0.6% +$33.2K
SNDA icon
46
Sonida Senior Living
SNDA
$1.93B
$6.23M 0.52%
+16,667
New +$5.88M
ASXC
47
DELISTED
Asensus Surgical, Inc.
ASXC
$6.1M 0.51%
161,208
+60,289
+60% +$2.49M
ADYX
48
DELISTED
Adynxx Inc
ADYX
$5.95M 0.5%
+18,699
New +$5.13M
CEMP
49
DELISTED
Cempra, Inc.
CEMP
$5.82M 0.49%
+247,500
New +$3.7M
LJPC
50
DELISTED
La Jolla Pharmaceutical Company
LJPC
$5.33M 0.45%
288,955
+38,955
+16% +$462K
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2014 Portfolio in Review

As of Q4 2014, Perceptive Advisors held 184 positions worth $1.19B, up 21% from $988M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Perceptive Advisors deployed $48.2M of net new capital in Q4 2014, opening 58 new positions and adding to 50 existing holdings. Its largest new stake was Bellicum Pharmaceuticals, Inc.: 104,640 shares worth $24.1M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 80% a quarter earlier, followed by Financials and Energy.

On the sell side, the largest reduction was Celgene Corp, an estimated $24.3M trimmed.

  • Perceptive Advisors's largest Q4 2014 buy was Bellicum Pharmaceuticals, Inc.: 104,640 shares worth $24.1M.
  • Perceptive Advisors added most to Amicus Therapeutics in Q4 2014, an estimated $14.4M increase.
  • Perceptive Advisors's biggest Q4 2014 reduction was Celgene Corp, cutting an estimated $24.3M.
  • Perceptive Advisors fully exited Arrowhead Research in Q4 2014, selling an estimated $18.4M.
  • Perceptive Advisors's ten largest holdings make up 42% of its $1.19B portfolio in Q4 2014.
  • Perceptive Advisors opened 58 new positions and closed 34 in Q4 2014.
  • Perceptive Advisors's portfolio value rose 21% quarter-over-quarter to $1.19B.

Based on Perceptive Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.